Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 Gag
AssigneeImmunocore Limited
InventorsTara Mahon, Yi Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to T cell receptors (TCRs) which bind the HLA-A*02 restricted peptide SLYNTVATL (SEQ ID NO: 1) derived from the HIV Gag gene product, p17. Said TCRs comprise non-natural mutations within the alpha and/or beta variable domains relative to a native HIV TCR. The TCRs of the invention possess unexpectedly high affinity, specificity and sensitivity for a complex of SEQ ID NO: 1 and HLA-A*02, and drive a particularly potent T cell response. Such TCRs are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of HIV infected individuals.
Claims10
A T-cell receptor (TCR) having the property of binding to SLYNTVATL (SEQ ID No:
- 1) in complex with HLA-A*02, comprising:
- a TCR alpha chain variable domain and
- a TCR beta chain variable domain, wherein
- the alpha chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:
- 6 or 7, and
- the beta chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.